Literature DB >> 16158829

Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation.

Takehiko Mori, Yoshinobu Aisa, Tomonori Nakazato, Yasuo Ikeda, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16158829     DOI： 10.1532/ijh97.05036

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

1.  Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin.

Authors:  Y Kanda; S Mineishi; K Nakai; T Saito; R Tanosaki; Y Takaue
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

2.  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Authors:  Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Yoo-Jin Kim; Sun Hee Park; Sun-Nam Park; Chang-Ki Min; Seok Lee; Hee-Je Kim; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Wan-Shik Shin; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

3.  Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.

Authors:  T Mori; S Okamoto; S Matsuoka; T Yajima; M Wakui; R Watanabe; A Ishida; Y Iwao; M Mukai; T Hibi; Y Ikeda
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

4.  Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation.

Authors:  T Mori; S Okamoto; R Watanabe; T Yajima; Y Iwao; R Yamazaki; T Nakazato; N Sato; T Iguchi; H Nagayama; N Takayama; T Hibi; Y Ikeda
Journal:  Bone Marrow Transplant       Date:  2002-05       Impact factor: 5.483

5.  Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin.

Authors:  K Nakai; Y Kanda; S Mineishi; T Saito; M Ohnishi; H Niiya; A Chizuka; T Takeuchi; H Matsubara; M Kami; A Makimoto; R Tanosaki; H Kunitoh; K Tobinai; Y Takaue
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483
  5 in total
  2 in total

1.  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Authors:  Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Yoo-Jin Kim; Sun Hee Park; Chang-Ki Min; Seok Lee; Hee-Je Kim; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Wan-Shik Shin; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

2.  Prevention of cytomegalovirus infection by valaciclovir after allogeneic bone marrow transplantation from an unrelated donor.

Authors:  Takehiko Mori; Yoshinobu Aisa; Takayuki Shimizu; Tomonori Nakazato; Rie Yamazaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.